Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment

Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells

(2015) Patrick J. Grohar et al.   NEOPLASIA

Abstract 2129: Aplidin triggers the activation of molecular components of the UPR as part of its pro-apoptotic program in tumor cells.

(2014) Alejandro Losada et al.   CANCER RESEARCH

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

(2013) Giovanni Germano et al.   CANCER CELL

The intriguing patterns of tumor response to trabectedin

(2013) Roberta Sanfilippo et al.   Expert Review of Anticancer Therapy

PPARγ agonists enhance ET-743–induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma

(2012) Elizabeth Charytonowicz et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting of the innate immunity/inflammation as complementary anti-tumor therapies

(2011) Giovanni Germano et al.   ANNALS OF MEDICINE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

XPF-Dependent DNA Breaks and RNA Polymerase II Arrest Induced by Antitumor DNA Interstrand Crosslinking-Mimetic Alkaloids

(2011) Sascha Feuerhahn et al.   CHEMISTRY & BIOLOGY

Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment

(2011) P. Allavena et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells

(2011) Pablo E. Morande et al.   INVESTIGATIONAL NEW DRUGS

Identification and manipulation of tumor associated macrophages in human cancers

(2011) Moniek Heusinkveld et al.   Journal of Translational Medicine

Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations

(2011) Juan A. Bueren-Calabuig et al.   NUCLEIC ACIDS RESEARCH

Tumor-Associated Macrophages as Incessant Builders and Destroyers of the Cancer Stroma

(2011) Manuela Liguori et al.   Cancers

Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment

(2010) A. J. Clear et al.   BLOOD

Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells

(2010) G. Germano et al.   CANCER RESEARCH

Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes

(2010) K. Movahedi et al.   CANCER RESEARCH

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

Molecular Pathways Linking Inflammation and Cancer

(2010) A. Mantovani   CURRENT MOLECULAR MEDICINE

Tumors as Organs: Complex Tissues that Interface with the Entire Organism

(2010) Mikala Egeblad et al.   DEVELOPMENTAL CELL

Chemokines in cancer related inflammation

(2010) Paola Allavena et al.   EXPERIMENTAL CELL RESEARCH

Alternative Activation of Macrophages: Mechanism and Functions

(2010) Siamon Gordon et al.   IMMUNITY

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

(2010) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Jekyll and Hyde: the role of the microenvironment on the progression of cancer

(2010) Michael Allen et al.   JOURNAL OF PATHOLOGY

A Review of Trabectedin (ET-743): A Unique Mechanism of Action

(2010) Maurizio D'Incalci et al.   MOLECULAR CANCER THERAPEUTICS

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

(2010) Subhra K Biswas et al.   NATURE IMMUNOLOGY

Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor β

(2009) Taku Nagai et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling

(2009) Kandice R. Levental et al.   CELL

A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates

(2009) M. Roycik et al.   CURRENT PHARMACEUTICAL DESIGN

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II Melanoma

(2009) Trine O. Jensen et al.   JOURNAL OF CLINICAL ONCOLOGY

The Extracellular Matrix: Not Just Pretty Fibrils

(2009) R. O. Hynes   SCIENCE

Von Hippel-Lindau-Coupled and Transcription-Coupled Nucleotide Excision Repair-Dependent Degradation of RNA Polymerase II in Response to Trabectedin

(2008) G. J. Aune et al.   CLINICAL CANCER RESEARCH

Prognostic Significance of Macrophage Infiltration in Leiomyosarcomas

(2008) C.-H. Lee et al.   CLINICAL CANCER RESEARCH

Macrophages define the invasive microenvironment in breast cancer

(2008) Jeffrey W. Pollard   JOURNAL OF LEUKOCYTE BIOLOGY

Tumour immunity: effector response to tumour and role of the microenvironment

(2008) Alberto Mantovani et al.   LANCET

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE